Recombinant Human CALCA protein

中文名： 降钙素基因相关肽 I(CALCA)重组蛋白
别名： CALCA；CALC1；Calcitonin gene-related peptide 1

货号: PA1000-4486

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	CALCA
Uniprot No	P01258
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	26-141aa
氨基酸序列	APFRSALESS PADPATLSED EARLLLAALV QDYVQMKASE LEQEQEREGS SLDSPRSKRC GNLSTCMLGT YTQDFNKFHT FPQTAIGVGA PGKKRDMSSD LERDHRPHVS MPQNAN
预测分子量	13 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于CALCA(降钙素基因相关肽，CGRP)重组蛋白的3篇代表性文献摘要示例：

1. **《Efficient expression and purification of recombinant human CGRP in Escherichia coli》**

- 作者：Smith J, et al. (2005)

- 摘要：研究报道了通过大肠杆菌系统高效表达人源CALCA重组蛋白(CGRP)的优化策略，采用His标签纯化技术获得高纯度蛋白，并通过体外血管舒张实验验证其生物活性，为大规模制备功能性CGRP提供方法学支持。

2. **《Recombinant CGRP modulates endothelial cell function in cardiovascular disease models》**

- 作者：Johnson L, et al. (2010)

- 摘要：利用哺乳动物细胞表达系统制备重组CGRP，发现其能显著增强血管内皮细胞一氧化氮合成，改善动脉粥样硬化模型中的血管舒张功能，提示其在心血管疾病治疗中的潜在应用价值。

3. **《Structural and functional analysis of CGRP using site-directed mutagenesis》**

- 作者：Zhang Y, et al. (2015)

- 摘要：通过定点突变技术构建多种CALCA重组蛋白变体，结合晶体结构分析和神经元活性实验，揭示CGRP的N端α-螺旋结构域对其受体结合及神经调节功能的关键作用。

注：以上文献信息为学术示例，实际引用时需核实真实存在的文献来源及细节。

背景信息

CALCA (calcitonin-related polypeptide alpha) is a gene that encodes two key bioactive peptides through alternative splicing: calcitonin and calcitonin gene-related peptide (CGRP). Recombinant CALCA proteins, particularly CGRP, have garnered significant attention due to their diverse physiological roles. CGRP, a 37-amino acid neuropeptide, functions as a potent vasodilator and neurotransmitter, playing critical roles in modulating pain perception, cardiovascular homeostasis, and inflammatory responses. It interacts with the CGRP receptor, a G protein-coupled receptor complex, influencing multiple signaling pathways.

Calcitonin, a 32-amino acid hormone, primarily regulates calcium-phosphate metabolism by inhibiting osteoclast activity and promoting renal calcium excretion. While native calcitonin has been used therapeutically for osteoporosis, recombinant CGRP has become more clinically relevant in recent years. Studies link CGRP to migraine pathophysiology, where its release from trigeminal nerves induces cerebral vasodilation and neurogenic inflammation. This led to the development of CGRP-targeting monoclonal antibodies and receptor antagonists for migraine prevention.

Recombinant CALCA proteins are typically produced in bacterial (e.g., E. coli) or mammalian expression systems, ensuring proper post-translational modifications for bioactivity. Their applications span basic research, drug discovery, and therapeutic development. In neuroscience, recombinant CGRP helps study nociceptive pathways, while in cardiovascular research, it aids in exploring blood pressure regulation. Pharmaceutical interest focuses on both agonists and antagonists of CGRP signaling, balancing therapeutic potential with safety profiles. Current challenges include optimizing receptor specificity and managing CGRP's dual role in protective vasodilation versus pathological inflammation. These recombinant proteins remain vital tools for understanding neuroendocrine-immune interactions and developing precision therapies.